Zhangzhou Pientzehuang Pharmaceutical., Ltd (SHA:600436)
China · Delayed Price · Currency is CNY 141.18
-0.01 (-0.01%)
May 8, 2026, 3:00 PM CST
SHA:600436 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 8,569 | 8,969 | 10,756 | 10,036 | 8,674 | 8,004 |
Other Revenue | 32.27 | 32.27 | 31.87 | 22.31 | 19.52 | 17.29 |
| 8,601 | 9,001 | 10,788 | 10,058 | 8,694 | 8,022 | |
Revenue Growth (YoY) | -20.05% | -16.56% | 7.25% | 15.70% | 8.38% | 23.20% |
Cost of Revenue | 5,591 | 5,732 | 6,189 | 5,363 | 4,735 | 3,968 |
Gross Profit | 3,010 | 3,270 | 4,599 | 4,695 | 3,959 | 4,054 |
Selling, General & Admin | 810.39 | 760.19 | 858.09 | 1,150 | 814.41 | 1,027 |
Research & Development | 268.87 | 252.23 | 269.59 | 232.35 | 230.03 | 199.51 |
Other Operating Expenses | 32.32 | 30.44 | 47.81 | 70.77 | 71.96 | 72.05 |
Operating Expenses | 1,131 | 1,072 | 1,178 | 1,465 | 1,110 | 1,306 |
Operating Income | 1,879 | 2,198 | 3,420 | 3,230 | 2,849 | 2,748 |
Interest Expense | -31.19 | -31.75 | -37.62 | -37.31 | -38.01 | -32.9 |
Interest & Investment Income | 378.75 | 367.91 | 182.59 | 170.81 | 171.62 | 144.48 |
Currency Exchange Gain (Loss) | -0.88 | -0.88 | 7.57 | 3.09 | 7.18 | -3.28 |
Other Non Operating Income (Expenses) | 4.19 | 5.12 | -3.03 | 6.02 | -36.47 | -21.62 |
EBT Excluding Unusual Items | 2,230 | 2,538 | 3,570 | 3,373 | 2,954 | 2,834 |
Gain (Loss) on Sale of Investments | -9.39 | -9.76 | -8.95 | 8.32 | -0.02 | 4.54 |
Gain (Loss) on Sale of Assets | 5.54 | 3.8 | 3.87 | 0.96 | 11.14 | 27.59 |
Asset Writedown | -0.83 | - | - | - | -0.33 | -1.02 |
Other Unusual Items | 5.61 | 5.61 | -25.92 | -13.06 | 13.18 | 3.55 |
Pretax Income | 2,231 | 2,538 | 3,539 | 3,369 | 2,978 | 2,869 |
Income Tax Expense | 361.32 | 394.55 | 543.21 | 517.77 | 454.76 | 404.23 |
Earnings From Continuing Operations | 1,870 | 2,143 | 2,996 | 2,851 | 2,523 | 2,465 |
Minority Interest in Earnings | 32.4 | 15.35 | -18.52 | -53.79 | -50.63 | -32.9 |
Net Income | 1,902 | 2,159 | 2,977 | 2,797 | 2,472 | 2,432 |
Net Income to Common | 1,902 | 2,159 | 2,977 | 2,797 | 2,472 | 2,432 |
Net Income Growth | -36.64% | -27.49% | 6.42% | 13.15% | 1.66% | 45.49% |
Shares Outstanding (Basic) | 604 | 603 | 604 | 603 | 603 | 603 |
Shares Outstanding (Diluted) | 604 | 603 | 604 | 603 | 603 | 603 |
Shares Change (YoY) | -0.09% | -0.15% | 0.16% | -0.02% | -0.07% | 0.00% |
EPS (Basic) | 3.15 | 3.58 | 4.93 | 4.64 | 4.10 | 4.03 |
EPS (Diluted) | 3.15 | 3.58 | 4.93 | 4.64 | 4.10 | 4.03 |
EPS Growth | -36.58% | -27.38% | 6.25% | 13.17% | 1.74% | 45.49% |
Free Cash Flow | 60.28 | -262.77 | 245.41 | 2,065 | 6,698 | 370.11 |
Free Cash Flow Per Share | 0.10 | -0.44 | 0.41 | 3.42 | 11.11 | 0.61 |
Dividend Per Share | 2.970 | 2.970 | 2.970 | 2.320 | 1.250 | 1.210 |
Dividend Growth | - | - | 28.02% | 85.60% | 3.31% | 34.44% |
Gross Margin | 35.00% | 36.32% | 42.63% | 46.68% | 45.54% | 50.53% |
Operating Margin | 21.85% | 24.42% | 31.70% | 32.11% | 32.77% | 34.25% |
Profit Margin | 22.12% | 23.98% | 27.60% | 27.81% | 28.44% | 30.32% |
Free Cash Flow Margin | 0.70% | -2.92% | 2.27% | 20.53% | 77.04% | 4.61% |
EBITDA | 1,966 | 2,278 | 3,475 | 3,298 | 2,897 | 2,854 |
EBITDA Margin | 22.85% | 25.30% | 32.21% | 32.79% | 33.32% | 35.58% |
D&A For EBITDA | 86.22 | 79.98 | 55 | 67.82 | 47.36 | 106.25 |
EBIT | 1,879 | 2,198 | 3,420 | 3,230 | 2,849 | 2,748 |
EBIT Margin | 21.85% | 24.42% | 31.70% | 32.11% | 32.77% | 34.25% |
Effective Tax Rate | 16.19% | 15.55% | 15.35% | 15.37% | 15.27% | 14.09% |
Revenue as Reported | 8,601 | 9,001 | 10,788 | 10,058 | 8,694 | 8,022 |
Advertising Expenses | - | 127.7 | 258.62 | 531.48 | 255.04 | 445 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.